MILAN, Jan. 19 (Class Editori) — Moderna wants to expand even more, continuing to ride the wave of success achieved through COVID-19 but also looking beyond it. To do so, it is planning to expand its mRNA vaccine production capacity, with the goal of making immunization products targeting different pathogens, as was explained by the US biotech’s CEO, Stéphane Bancel, at the World Economic Forum in Davos.
Bancel also told Reuters that the company is negotiating with China to supply the Asian country with its COVID-19 vaccines, adding that they are also talking about factories and the supply of other products, including cancer treatments.
Moderna’s goal is to get to build factories in order to produce mRNA vaccines on all continents in a short period of time, the CEO explained, specifying that the biotech company is already negotiating with several countries and has started design and construction activities for new factories in Canada, Australia, Great Britain, and Kenya. Moderna’s COVID-19 vaccines are currently produced in the US and Switzerland only.
The company’s plans also include the reduction of the production time for the new COVID-19 boosters by at least two weeks, an acceleration that would benefit any new booster that may be needed ahead of the fall of 2023 and 2024.
Moderna is also aiming to grow beyond COVID-19 by expanding its pipeline through the results of a large clinical trial the biotech is conducting on its respiratory syncytial virus (RSV) vaccine, which has been shown to significantly reduce the risks of respiratory disease in adults.
In order to value its efficacy, Moderna counted cases of RSV infections with at least two symptoms, such as cough, fever, or difficulty breathing. Bancel’s company plans to apply for the approval of this vaccine to the US Food and Drug Administration (FDA) in order to bring it to the market. If the project gets a green light, the product could be available by early 2024.
(Source:Class Editori)
Notice: No person, organization and/or company shall disseminate or broadcast the above article on Xinhua Silk Road website without prior permission by Xinhua Silk Road.
A single purchase
